BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Weersink RA, Burger DM, Hayward KL, Taxis K, Drenth JP, Borgsteede SD. Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations. Expert Opinion on Drug Metabolism & Toxicology 2020;16:45-57. [DOI: 10.1080/17425255.2020.1702022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Johnson AL, Hayward KL. Managing medicines in alcohol-associated liver disease: a practical review. Aust Prescr 2021;44:96-106. [PMID: 34211248 DOI: 10.18773/austprescr.2021.015] [Reference Citation Analysis]
2 Oh H, Lee JH. Tivozanib in advanced inoperable hepatocellular carcinoma: considerations for patients with liver cirrhosis. Ann Transl Med 2020;8:1530. [PMID: 33313275 DOI: 10.21037/atm-20-3526] [Reference Citation Analysis]
3 El-Khateeb E, Al-Majdoub ZM, Rostami-Hodjegan A, Barber J, Achour B. Proteomic Quantification of Changes in Abundance of Drug-Metabolizing Enzymes and Drug Transporters in Human Liver Cirrhosis: Different Methods, Similar Outcomes. Drug Metab Dispos 2021;49:610-8. [PMID: 34045218 DOI: 10.1124/dmd.121.000484] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Hayward KL, Valery PC, Patel PJ, Li C, Horsfall LU, Wright PL, Tallis CJ, Stuart KA, David M, Irvine KM, Cottrell N, Martin JH, Powell EE. Medication Discrepancies and Regimen Complexity in Decompensated Cirrhosis: Implications for Medication Safety. Pharmaceuticals (Basel) 2021;14:1207. [PMID: 34959611 DOI: 10.3390/ph14121207] [Reference Citation Analysis]
5 Hayward KL, Weersink RA. Improving Medication-Related Outcomes in Chronic Liver Disease. Hepatol Commun 2020;4:1562-77. [PMID: 33163829 DOI: 10.1002/hep4.1612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Thomson MJ, Lok ASF, Tapper EB. Appropriate and Potentially Inappropriate Medication Use in Decompensated Cirrhosis. Hepatology 2021;73:2429-40. [PMID: 32911564 DOI: 10.1002/hep.31548] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Bianco C, Coluccio E, Prati D, Valenti L. Diagnosis and Management of Autoimmune Hemolytic Anemia in Patients with Liver and Bowel Disorders. J Clin Med 2021;10:423. [PMID: 33499290 DOI: 10.3390/jcm10030423] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Akkerman-Nijland AM, Akkerman OW, Grasmeijer F, Hagedoorn P, Frijlink HW, Rottier BL, Koppelman GH, Touw DJ. The pharmacokinetics of antibiotics in cystic fibrosis. Expert Opin Drug Metab Toxicol 2021;17:53-68. [PMID: 33213220 DOI: 10.1080/17425255.2021.1836157] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]